Meredith Quarles, PA
Medical · Appomattox, VANPI 1104225101
Payments from drug & device makers
Across 728 payments — averaging $14.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$2K
- AbbVie$2K
- AstraZeneca$1K
- Pfizer$942
- Lilly USA, LLC$846
- Johnson & Johnson$530
- plus $3K from 30 others
What the payments were for
- Food & beverage$10,827100%
- Education$70%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 133 | $2,060 |
| AbbVie | 152 | $1,893 |
| AstraZeneca(2 entities) | 39 | $1,274 |
| Pfizer | 87 | $942 |
| Lilly USA, LLC | 47 | $846 |
| Johnson & Johnson | 42 | $530 |
| Amgen | 31 | $425 |
| Abbott | 20 | $413 |
| Boehringer Ingelheim | 21 | $304 |
| Biohaven Pharmaceutical Holding Company Ltd. | 37 | $295 |
| GSK | 17 | $259 |
| Biohaven Pharmaceuticals, Inc. | 15 | $248 |
| Esperion Therapeutics, Inc. | 10 | $184 |
| Takeda Pharmaceuticals U.S.A., Inc. | 13 | $134 |
| Exact Sciences | 7 | $128 |
| Dexcom, Inc. | 8 | $123 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 5 | $87 |
| Nestle Healthcare Nutrition Inc. | 5 | $82 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $81 |
| Otsuka America Pharmaceutical, Inc. | 5 | $79 |
| Merck | 4 | $65 |
| Astellas Pharma US Inc | 4 | $57 |
| Novartis | 3 | $50 |
| Idorsia Pharmaceuticals US Inc | 3 | $44 |
| Sanofi-aventis U.S. LLC | 2 | $31 |
| E.r. Squibb & Sons, L.L.C. | 2 | $29 |
| Sanofi Pasteur Inc. | 2 | $26 |
| Corcept Therapeutics | 1 | $21 |
| Neurocrine Biosciences, Inc. | 1 | $20 |
| Phathom Pharmaceuticals, Inc. | 1 | $19 |
| Sumitomo Pharma America, Inc. | 1 | $17 |
| Amarin Pharma, Inc. | 1 | $16 |
| Vanda Pharmaceuticals Inc. | 1 | $16 |
| Bayer | 1 | $13 |
| Genentech USA, Inc. | 1 | $12 |
| Teva Pharmaceuticals USA, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$10,834 in reported general payments places this provider in the 95th percentile of 632 medical providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 105 | $124,778 |
| OzempicSemaglutide | 78 | $95,166 |
| EliquisApixaban | 91 | $79,602 |
| MounjaroTirzepatide | 46 | $48,116 |
| RybelsusSemaglutide | 21 | $43,037 |
| JanuviaSitagliptin Phosphate | 31 | $38,138 |
| TrulicityDulaglutide | 26 | $33,650 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 51 | $31,876 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 39 | $28,432 |
| FarxigaDapagliflozin Propanediol | 28 | $27,572 |
| XareltoRivaroxaban | 25 | $26,697 |
| LinzessLinaclotide | 26 | $26,214 |
| Tresiba Flextouch U-200Insulin Degludec | 11 | $24,011 |
| Aimovig AutoinjectorErenumab-Aooe | 28 | $20,064 |
| VraylarCariprazine Hcl | 12 | $16,888 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $2,060 | $138,20399 claims |
| Boehringer IngelheimJardiance | $304 | $124,778105 claims |
| Lilly USA, LLCMounjaro, Trulicity | $846 | $81,76572 claims |
| PfizerEliquis | $942 | $79,60291 claims |
| AstraZenecaBreztri Aerosphere, Farxiga, Symbicort | $1,274 | $58,38578 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta | $259 | $48,42482 claims |
| AbbVieLinzess, Vraylar, Synthroid | $1,893 | $45,02564 claims |
| MerckJanuvia | $65 | $38,13831 claims |
| Johnson & JohnsonXarelto | $530 | $26,69725 claims |
| Astellas Pharma US IncMyrbetriq | $57 | $8,80117 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 632 medical providers in Virginia.
Other medical in Appomattox
- Bryan UrquhartFredericksburg$264K
- Sara VillalonaRichmond$240K
- Sarah SafaLansdowne$171K
- Waseem GarbiaFairfax$114K
- Rana HassanAshburn$54K
- Brian LamFalls Church$51K
- Christine KesslerKing George$20K
- Janlyn AnthonyRichmond$18K
- Cara DepanfilisNorfolk$17K
- Nicholas DeptulaRichmond$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.